TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04614883

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis
Description: VOC analysis in exhaled air with e-noses and mass spectrometry. VOC analysis in sweat with mass spectrometry.

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis
Description: VOC analysis in exhaled air with e-noses and mass spectrometry. VOC analysis in sweat with mass spectrometry.
Study: NCT05140629

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo OGTT
Description: After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
Study: NCT02715362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAI-GPC3-CART cells
Description: TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
Study: NCT03809806

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 4-arm polypropylene mesh surgery
Description: Pelvic reconstructive procedures were performed with the use of 4-arm mesh:upper arms through- anterior part of obturator foramens, lower arms-ischiorectal fossas and sacrospinal ligaments.
Study: NCT04614883

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis
Description: VOC analysis in exhaled air with e-noses and mass spectrometry. VOC analysis in sweat with mass spectrometry.

Intervention type: OTHER
Group type: OTHER
Intervention: Canine odor detection of Volatile Organic Compounds
Description: VOC analysis in sweat by trained dogs.

Intervention type: OTHER
Group type: OTHER
Intervention: Canine odor detection of Volatile Organic Compounds
Description: VOC analysis in sweat by trained dogs.

Intervention type: OTHER
Group type: OTHER
Intervention: Canine odor detection of Volatile Organic Compounds
Description: VOC analysis in sweat by trained dogs.
Study: NCT01258062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GelVac™ nasal powder H5N1 influenza vaccine.
Description: subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
Study: NCT00102531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin liposomal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin liposomal
Study: NCT02155673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: 1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: 1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.
Study: NCT03614468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formula A
Description: Formula A is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formula B
Description: Formula B is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
Study: NCT03200704

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IC2000 and SPY-PHI
Description: Investigational treatment to assess the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tc-99m radioactive colloid and Gamma Probe
Description: Comparator; standard of care for sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
Study: NCT03583060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness in body-oriented therapy
Description: teaches interoceptive awareness skills for self care
Study: NCT04218864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength for U in Relationship Empowerment (SURE)
Description: A brief computer-based intervention (one session plus one booster session) based on motivational interviewing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention, time, and information matched control
Description: A brief computer based intervention (one session plus booster session) that involves viewing of popular television shows
Study: NCT00023283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 1. Experimental Standard Medical Management with once-weekly medication dispensing~2. Experimental Standard Medical Management with thrice-weekly medication dispensing~3. Experimental Enhanced Medical Management with thrice-weekly medication dispensing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 1. Experimental Standard Medical Management with once-weekly medication dispensing~2. Experimental Standard Medical Management with thrice-weekly medication dispensing~3. Experimental Enhanced Medical Management with thrice-weekly medication dispensing
Study: NCT01148303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04013360

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breath Stacking
Description: The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breath Stacking
Description: The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory Positive Airway Pressure
Description: Patients will perform exhalation of air through a facial mask containing an extrinsic positive expiratory pressure valve with a defined load of 10 cmH2O for 5 min. During the application of the technique the patients will have a trunk inclined 30º and will be stimulated to breathe normally, without effort or deep and fast breaths.
Study: NCT03559218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeraStat(R) Cream
Description: KeraStat Cream is a cream wound dressing that contains 5% keratin.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Patients will be instructed to follow institutional standard of care for radiation dermatitis
Study: NCT01369238

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bee Venom Acupuncture Therapy
Description: 1:4000, SC 1cc/day, 2\~3days/wk, for 1 month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bee Venom Acupuncture Therapy
Description: 1:4000, SC 1cc/day, 2\~3days/wk, for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zaltoprofen
Description: 80mg/Tab, per os 1Tab tid, for 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zaltoprofen
Description: 80mg/Tab, per os 1Tab tid, for 2 months
Study: NCT02962856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: 50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. (Formulation: Z43-078)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated Skin
Description: This site is patched without treatment as irradiated control
Study: NCT00421213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darinaparsin
Description: 300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.
Study: NCT03066843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA (5-aminolevulinic acid)
Description: ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA (5-aminolevulinic acid)
Description: ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light therapy
Description: Subjects will be exposed to blue light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light therapy
Description: Subjects will be exposed to blue light
Study: NCT02671383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir
Description: Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
Study: NCT04244396

Intervention type: DEVICE
Intervention: TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)
Description: TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.
Study: NCT03809806

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: The Female Sexual Function Index (FSFI) questionnaire
Description: patients fulfilled questionnaire before and 1 year after procedure

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: King Health Questionnaire (KHQ)
Description: patients fulfilled questionnaire before and 1 year after procedure
Study: NCT01615354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleglitazar
Description: Multiple oral doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microgynon®
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: Multiple oral doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple oral doses
Study: NCT01645826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem Hydrochloride
Description: The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
Study: NCT00023283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 1. Experimental Standard Medical Management with once-weekly medication dispensing~2. Experimental Standard Medical Management with thrice-weekly medication dispensing~3. Experimental Enhanced Medical Management with thrice-weekly medication dispensing
Study: NCT02397070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jaw exercise program
Description: The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal Splint and counseling
Description: The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
Study: NCT04487210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: MVC-COV1901 is formulated in the different dosages of Spike (S) protein with CpG 1018 and aluminum content as adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: MVC-COV1901 is formulated in the different dosages of Spike (S) protein with CpG 1018 and aluminum content as adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: MVC-COV1901 is formulated in the different dosages of Spike (S) protein with CpG 1018 and aluminum content as adjuvant.
Study: NCT01140074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc Sulfate
Description: Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
Study: NCT00663559

Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib
Description: Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
Study: NCT01215942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered Subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered Subcutaneously
Study: NCT00261196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase
Description: Anterior shoulder capsule injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Collagenase
Description: Anterior shoulder capsule injection
Study: NCT00536575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose Levels 1 and 2: 200 mg by mouth twice daily~Dose Level 3: 400 mg by mouth twice daily
Study: NCT01645826

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
Study: NCT03861858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-A
Description: DBT-A is a multimodal therapy which consists of weekly individual therapy, weekly multifamily skills groups, as needed phone coaching, and weekly consultation team for the therapists.
Study: NCT02760056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liothyronine sodium
Description: Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive a matching placebo to take twice daily for one week.
Study: NCT03400501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Single daily dose of insulin degludec based on their fasting blood glucose levels and current long acting insulin dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Single daily dose of insulin glargine based on their fasting blood glucose levels and current long acting insulin dose
Study: NCT04013360

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory Positive Airway Pressure
Description: Patients will perform exhalation of air through a facial mask containing an extrinsic positive expiratory pressure valve with a defined load of 10 cmH2O for 5 min. During the application of the technique the patients will have a trunk inclined 30º and will be stimulated to breathe normally, without effort or deep and fast breaths.
Study: NCT02393807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF 06260414 solid dose formulation
Description: Single dose of 30 mg PF-06260414 given under fed/fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06260414 nanosuspension
Description: Single dose of 30 mg PF-06260414 given under fasted conditions
Study: NCT03283293

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Target Volume Delineation after NACT
Description: The gross tumor volumes of the primary site and the neck nodes (GTVnx and GTVnd) were delineated in accordance with the head and neck magnetic resonance imaging (MRI) and endoscopy, which obtained two weeks after the last cycle of NACT. The first clinical target volume (CTV1) was defined as the GTVnx plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the high-risk sites of microscopic extension, the whole nasopharynx, and the location and extent of the primary tumor before NACT. The second clinical target volume (CTV2) was defined as the CTV1 plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the low-risk sites of microscopic extension, the level of the lymph node located before NACT, and the elective neck area. The prescribed dose to GTVnx, GTVnd, CTV1 and CTV2 were 68Gy/30f, 62-66Gy/30f, 60Gy/30f and 54Gy/30f, respectively.
Study: NCT02805179

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Radiation
Description: Radiation will be delivered once daily for a total of 30 fractions, five days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will receive concurrent temozolomide (75 mg/m\^2 daily for 6 weeks). Adjuvant temozolomide will be given at 150-200 mg/m\^2, D1-5 every 28 days for a minimum of six cycles and will be started approximately four weeks following completion of radiotherapy.
Study: NCT03999736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation using a Soterix mini-CT device
Description: TDCS is used to non-invasively stimulate the brain through the application of electrical currents to a small region of the scalp using a battery-powered stimulator (Soterix Medical 2018) with rubber electrodes and conductive material (saline-soaked sponges). Both electrodes are attached to the scalp with a band. The stimulation points will be located using the 10-20 system of electroencephalogram (EEG) electrode location (localization carried out using a bespoke head strap). The electrode size of the stimulator used in this study is large (25 cm2) and the current strength used is low (2 mA) resulting in very low current density (0.08 mA/cm2). This protocol applies no more than 30 minutes of stimulation in a single session, which is typical for experimental studies (Brunoni et al. 2015; Loo et al. 2017). TDCS is an investigational device and has proceeded with a non-significant risk designation in many past trials and not required an investigational device exemption from the FDA.
Study: NCT02808728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pain Cocktail with Exparel
Description: pain cocktail: bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel (bupivacaine liposome injectable suspension), 20cc of 1.3% Exparel, to total 100cc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pain Cocktail with Ropivacaine
Description: pain cocktail: ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.